Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Looks promising hopefully it get through trials.
Would mean even more sales of Keytruda, currently $12billion odd annually.
Could we have an Keytruda mimetic affimer?
Thats the thing its very possible, we have undisclosed affimers in TMAC.. The affimer IP is Incredible.
Goid spot Monkshood, 9000 odd false positives and that number will only rise with more lft usage.
Specificity and NPV will be ever more important when prevalence rates are very low and lft use is in the millions per day.
This is when a test with extremely high specificity will rule them all.
Hopefully Avacta specificity will indeed be our USP.
Interesting reading thanks for the link Mart.
Also interesting to note the PPV of all the tests in low prevalence setting of 1%.
"In low prevalence settings, Ag-RDTs will have a high NPV but a low PPV.
According to our estimate, the NPV for SARS-CoV-2 infections at 1% prevalence was higher
than 99% for all test, suggesting that a negative test may not require confirmation. In contrast,
the PPV at 1% prevalence was lower than 50% in all tests, suggesting that a positive result will
need immediate confirmation by RT-qPCR, even for highly specific assays."
The above I think really sets the case for a very highly specific test to gain a high PPV in low prevalence mass testing situations.
I really hope that this is what will set us apart from all the others.
Cheers Speranza I never knew that, its a bit confusing looking at the info on their site.
Also for people who where suggesting from the variants RNS that our LFT could only detect the B117 Kent variant and not the Brazil or SA etc.
This Gov website dated 8th Feb states the same for Surescreen, so all good.
https://www.gov.uk/government/news/british-manufacturer-surescreen-diagnostics-to-supply-20-million-rapid-lateral-flow
"The tests have already been validated by PHE in the lab and are now in their final stage of validation in clinical trials. The tests have been proven to detect the B117 ‘Kent’ variant of COVID-19, and are already CE marked and MHRA registered."
Of note though is that it states in the final stages of clinical trails, wonder how that has went?
MrAdventurous, it appears that Surescreens is also AN.
Shown in the demo video below;
https://www.primarycaresupplies.co.uk/surescreen-covid-19-rapid-antigen-test/
"Planning, directing the activities of the development team to enable the development of novel rapid diagnostic tests and facilitate their transfer into Omega Diagnostic’s manufacturing facility."
Wha wha wha... what?? But Merchant said this would never happen, never trust a b******!!
Just a thought Raprap you said "I don't know how they would do it be it 2 strips 1s 1n or 1 strip with s&n but I don't think it would take that long to refine it."
Would the addition of N with S in a test be a real benefit? assuming they are on the same strip then surely sensitivity would be at least the same or better, but for specificity would it not be a case of the lowest common denominator, for example if N specificity was 90% and S 95% then wouldn't it be the lowest at 90% as N would still throw up 10% false positives.
Maybe im over thinking this and someone more knowledgeable could elaborate?
Anyway the clinical data from Mologic with N test certainly was nowhere near the initial Avacta S test data and hopefully that will carry forward into our CV.
On several news sites, WHO warns that vaccination is not substitute for prevention in fight against COVID-19
Chile is leading the way in the world with one of the fastest vaccination campaigns, yet a surge in COVID-19 cases has put the nation's health service on the brink of collapse.
The rate of immunization in Chile has far outpaced its neighbors in Latin America, and globally, it is just behind Israel, the United Arab Emirates and the UK.
The Latin American nation, which has a population of over 19 million, has secured more than 35 million vaccination doses for 2021 to the extent that experts say the country could be one of the first in the world to achieve herd immunity. Nearly 40% of Chileans have received at least one dose of a vaccine.
However, a second wave of the virus is ripping through the country, which has one of the highest COVID-19 mortality rates in Latin America. Daily coronavirus infections show record figures, exceeding 7,000 cases per day in the last week. To date, Chile has more than 23,000 deaths and nearly one million cases.
The increase in COVID-19 infections has triggered a new series of strict lockdown measures. More than 80% of the country’s population is not allowed to leave their homes even to buy groceries or pharmacy supplies. Each person is allowed two short-term permits to leave the house only to buy essentials.
President Sebastian Pinera even asked Congress to postpone municipal and regional elections that were scheduled to be held on April 10 and 11 due to a rise in coronavirus cases.
Experts say mass vaccination began when there was a high level of contagion, a consequence of increasingly lax containment measures. The worrying upward trend led the World Health Organization (WHO) to warn that vaccination is not a substitute for infection prevention measures.
"After the distribution of vaccines, there are those who fail to comply with measures such as physical distancing, hand hygiene, ventilation or avoidance of crowded places, and all this must continue along with vaccination," said Maria Van Kerkhove, the WHO’s COVID-19 technical lead.???????
For now, and during the vacation season in Chile, the government has tightened restrictions for travelers. People who enter the country from March 31 will now have to stay in a hotel for five days at their own expense before completing five more days of quarantine.
Retireby40 I run my own small business, tbh its just me.
From my own loint of view I would gladly take a regular test and isolate if positive but if I didnt have a high confidence in the positive result I wouldn't be very keen on doing the test at all.
Thanks for that link and your thoughts Monks.
I read through some of these papers but being a mere fridge guy a lot still goes over the head.
Regarding AS choice of targeting of the spike, as you mention most LFTs are targeting N some of which have very good sensitivity and good specificity.
The first paper linked shows higher specificity of S compared to N and with AS also targeting S with a highly specific affimer, this is exactly whats needed for very low false positives, especially in rates of low prevelence.
This is what AS has been stating all along, a test sensitive enought to catch the infectious but also exquisitely specific to prevent the economic and social issues of large amounts of false positives.
I think the issue of false positives is possibly more important than false (possibly non infectious) negatives from the point of view of mass testing and acceptence by the population.
If too many people get a positive leading to isolation and disruption of their lives only to later find that it was a false positive then faith will soon be lost.
Roll on the CV results I am hoping for world beating specifity and very good sensitivity.
I know its been commonly stated here the issues with frozen Porton Down samples but this is the first i have seen such publicized.
Dated 25th March 2021
The variability between preparations suggested a fragile S ectodomain. Indeed, such fragility and measures to overcome have been previously reported (11, 12). We traced the apparent spike fragility to rapid deterioration upon storage at 4 °C (Figure 1 B-E), and hypothesized that the stabilized SARS-CoV-2 S ectodomain is a cold-sensitive protein.
https://link.springer.com/article/10.1007/s00216-021-03298-4
N1 PL not trying to big it up but its only a fraction of my holding here so will be very happy for it to boom.
xNoxz, Ginge I wanted the profit from this in this tax year and I also understand that it takes a few days for funds to clear anyway. Although that may be wrong?